personalised-1-list [M04]

Personalised treatment with Flebogamma® DIF

Flebogamma® DIF is convenient for you and your patients; it is offered in 5% and 10% concentrations and a wide range of vial sizes

Flebogamma® DIF is convenient for:

  • Your patients
    • Patient risk factors and certain clinical conditions should be considered when selecting which concentration of IVIG to use
  • Your clinical practice
    • Ready-to-use liquid
    • Storable at room temperature (<30°C)* for the entire 2-year shelf life1

personalised-2-pic [M06]

5% & 10% Concentration

personalised-3-list [M06]

5% concentration

  • It may be an appropriate choice for patients who have frequent adverse reactions to infusions of IVIG2
  • It may be suitable also for patients who would benefit from additional fluid2
  • It may be appropriate for patients with renal dysfunction due to its lower osmolality and absence of sucrose, maltose or glucose2

10% concentration

  • It can be infused in a lower volume being able to meet the needs of patients at risk of volume overload, including patients with heart failure3

personalised-4-pics [M06]

With Flebogamma® DIF, in its wide range of vial sizes, you can personalize dosing and provide a more convenient IG treatment1

Flebogamma DIF 5% Flebogamma DIF 10%

personalised-5-pic [M05] left

Concentration matters: consider Flebogamma® DIF 5% for your high-risk patients

Silhouettes of patients

Flebogamma® DIF 5% may be an appropriate choice for many of your patients, including those who cannot tolerate a 10% IVIG solution

In a recent trial with Flebogamma® DIF the frequency of infusions with potentially treatment-related AEs with the 5% concentration was 2.2%4

Patient with doctor dialogue

Patient risk factors and certain clinical conditions should be considered when selecting which concentration of IVIG to use3

High-concentration product is among the factors that predispose patients to a higher rate of systemic adverse reactions5

Patients walking arm in arm

Flebogamma® DIF contains low levels of isoagglutinin antibodies, and therefore may be a suitable choice for patients at increased risk of hemolysis6,7



  1. Flebogamma® DIF EU SmPC.
  2. Gürcan HM, Keskin DB, Ahmed AR. Information for healthcare providers on general features of IGIV with emphasis on differences between commercially available products. Autoimmun Rev. 2010;9(8):553-559.
  3. Gelfand EW. Differences between IGIV products: impact on clinical outcome. Int Immunopharmacol. 2006;6(4):592-599.
  4. Alsina L, Mohr A, Montañés M, et al. Surveillance study on the tolerability and safety of Flebogamma® DIF (10% and 5% intravenous immunoglobulin) in adult and pediatric patients. Pharmacol Res Perspect. 2017 Oct;5(5).
  5. Bonilla FA. Intravenous immunoglobulin: adverse reactions and management. J Allergy Clin Immunol. 2008;122(6):1238-1239.
  6. Bellac CL, Hottiger T, Jutzi MP, et al. The role of isoagglutinins in intravenous immunoglobulin-related hemolysis. Transfusion. 2015;55:S13-S22.
  7. Jorquera JI. Flebogamma 5% DIF development: rationale for a new option in intravenous immunoglobulin therapy. Clin Exp Immunol. 2009;157(suppl 1):17-21.